Clinical trials
Phase 1/2 Neuromyelitis Optica trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
12 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 5 |
| Not yet recruiting | 3 |
| Recruiting | 2 |
| Terminated | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Tianjin Medical University General Hospital | 3 |
| CRISPR Therapeutics | 1 |
| Fu-Dong Shi | 1 |
| Icahn School of Medicine at Mount Sinai | 1 |
| ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. | 1 |
| Mayo Clinic | 1 |
| Northwestern University | 1 |
| Shenzhen Beike Bio-Technology Co., Ltd. | 1 |
| Tang-Du Hospital | 1 |
| University of Calgary | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neuromyelitis Optica | 12 |
| Multiple Sclerosis, Chronic Progressive | 2 |
| Autoimmune Diseases of the Nervous System | 1 |
| Myasthenia Gravis | 1 |
| Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease | 1 |
| Myositis | 1 |
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 |
| Stiff-Person Syndrome | 1 |
Trials
Showing 76 to 12 of 12. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.